Life With GLP-1s
Clinical and cultural conversations around obesity have long revolved around BMI (and its credibility), harmful stereotypes, issues of equity and the multi-million dollar weight loss industry.
Read Resource
Prediabetes
-
-
How to Combat Muscle Loss While Taking GLP-1s
A side-effect of taking GLP-1s is a loss of muscle mass. Julie Mulcahy, PT, DPT, CAPP OB explores how to combat this with resistance exercises.
Read Article
-
The Science Behind Dieting, and Why it Doesn’t Work
Lisa McCormick, FNP-BC, RD, CDCES explores the science behind dieting and why it doesn't work. Find out more about sustainable weight loss!
Read Article
-
New Data Published by Omada Health Demonstrates the Impact of Coupling GLP-1s and Behavior Change Programming
Findings show that meaningfully engaged Omada members on GLP-1s achieved an average of 1.7 times greater weight loss, and inform a new collaboration with Evernorth's EncircleRx program.
Read Article
-
Webinar: Weight loss can’t cure obesity – So what can?
Obesity is now widely recognized as a lifelong chronic disease–but what’s behind that evolution? Join us to find out!
Read Article
-
NEBGH: 13th Annual Health and Wellness Benefits Conference
Leading Innovation at NEBGH 13th Annual Health and Wellness Benefits Conference
Read Article
-
HLTH 2024
Join Us at HLTH 2024 in Las Vegas!
Read Article
-
AHIP 2024 Consumer Experience & Digital Health Forum
Pioneering Transformation at AHIP 2024 Consumer Experience and Digital Health Forum
Read Article
-
AHIP 2024
Omada Health: Shining as a Gold Level Sponsor at AHIP 2024!
Read Article
-
Lockton People Solutions Conference
Charting New Frontiers at the Lockton People Solutions Conference 2024
Read Article
-
Thrive Summit 2024
A proud Gold Sponsor of the 2024 Thrive experience! Join our leaders, Tom Maraday and Kevin Masci on Thursday, April 11!
Read Article
-
Omada Health Expands Insights Lab to Advance Industry Learnings on Long-Term Weight Health
Building on more than a decade of insights and 28 peer-reviewed publications, Omada announces plans to develop more learnings focused on the long-term outcomes of GLP-1s on weight health
Read Article
-
Omada Health’s Guide to GLP-1s
Omada delivers GLP-1 FAQs focusing on weight loss quantity vs. quality with timely data and insights for employers, health plans and benefit consultants.
Read Article
-
Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population
In this study we examine the outcomes of a Medicare population who participated in a program combining digital health with human coaching for diabetes risk reduction.
Read Resource
-
Can I Trust a Healthcare App with my Data? It Depends
With more than eight in 10 U.S. adults now using digital health tools it is more important than ever for us to ensure that health data is secure.
Read Article
-
Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support
Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support.
Read Article
-
GLP-1 Demand Spotlights Existing Inequities in Obesity Care
Obesity is one of the clearest case studies of health disparities that exist in the U.S., having the biggest impact on Black and Hispanic adults, low-income populations, and people covered by Medicaid
Read Article
-
When Will GLP-1 Prices Drop?
GLP-1 agonist medications have had impressive initial outcomes. However, the long-term effects on a patient’s health beyond the trial timelines and on the costs to the healthcare system are uncertain.
Read Article
-
528.4 Billion Reasons Medication Optimization Matters
Medication optimization ensures that the right patient gets the right medication at the right time. Unfortunately it’s not always feasible.
Read Article
-
Will Healthcare Ever Reach Seamless Interoperability?
The success of virtual care across the US healthcare system will hinge on the seamless integration between virtual care solutions and electronic health records (EHRs) to optimize care delivery.
Read Article
-
Loading More...
